Ignyta, Inc. (NASDAQ:RXDX) – Stock analysts at Jefferies Group lifted their FY2017 earnings per share estimates for Ignyta in a research note issued to investors on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will earn ($2.41) per share for the year, up from their prior forecast of ($2.54). Jefferies Group also issued estimates for Ignyta’s Q4 2017 earnings at ($0.46) EPS, FY2018 earnings at ($2.23) EPS, FY2019 earnings at ($1.10) EPS, FY2020 earnings at $0.54 EPS and FY2021 earnings at $1.90 EPS.

Several other brokerages have also recently commented on RXDX. Zacks Investment Research raised shares of Ignyta from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Tuesday. BidaskClub cut shares of Ignyta from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price target on shares of Ignyta in a research report on Wednesday, September 27th. Ladenburg Thalmann Financial Services increased their price target on shares of Ignyta from $20.25 to $31.00 in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $20.00 price target (up previously from $18.00) on shares of Ignyta in a research report on Thursday, October 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.80.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/15/fy2017-eps-estimates-for-ignyta-inc-rxdx-increased-by-analyst.html.

Ignyta (RXDX) opened at $16.00 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.07 and a current ratio of 6.07. Ignyta has a 12-month low of $4.60 and a 12-month high of $18.30.

Ignyta (NASDAQ:RXDX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.03.

A number of hedge funds and other institutional investors have recently modified their holdings of RXDX. Wells Fargo & Company MN lifted its holdings in Ignyta by 4.8% in the first quarter. Wells Fargo & Company MN now owns 21,885 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 1,000 shares during the last quarter. American International Group Inc. lifted its holdings in Ignyta by 7.1% in the first quarter. American International Group Inc. now owns 18,148 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 1,197 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Ignyta by 2.9% in the first quarter. TIAA CREF Investment Management LLC now owns 128,339 shares of the biopharmaceutical company’s stock worth $1,104,000 after acquiring an additional 3,611 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Ignyta by 10.4% in the first quarter. Vanguard Group Inc. now owns 1,228,177 shares of the biopharmaceutical company’s stock worth $10,562,000 after acquiring an additional 115,212 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Ignyta by 4.5% in the first quarter. Geode Capital Management LLC now owns 241,615 shares of the biopharmaceutical company’s stock worth $2,077,000 after acquiring an additional 10,471 shares during the last quarter. 67.98% of the stock is currently owned by hedge funds and other institutional investors.

About Ignyta

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Earnings History and Estimates for Ignyta (NASDAQ:RXDX)

Receive News & Stock Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related stocks with our FREE daily email newsletter.